Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technol… Read more
Kuros Biosciences AG (CSBTF) - Total Assets
Latest total assets as of June 2025: $109.97 Million USD
Based on the latest financial reports, Kuros Biosciences AG (CSBTF) holds total assets worth $109.97 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kuros Biosciences AG - Total Assets Trend (2004–2024)
This chart illustrates how Kuros Biosciences AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kuros Biosciences AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Kuros Biosciences AG's total assets of $109.97 Million consist of 52.9% current assets and 47.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.7% |
| Accounts Receivable | $14.93 Million | 17.7% |
| Inventory | $9.44 Million | 11.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.99 Million | 17.7% |
| Goodwill | $19.43 Million | 23.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Kuros Biosciences AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kuros Biosciences AG's current assets represent 52.9% of total assets in 2024, a decrease from 76.1% in 2004.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2024, down from 23.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 23.0% of total assets.
Kuros Biosciences AG Competitors by Total Assets
Key competitors of Kuros Biosciences AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Kuros Biosciences AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Kuros Biosciences AG generates 0.89x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kuros Biosciences AG is currently not profitable relative to its asset base.
Kuros Biosciences AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.25 | 2.73 | 5.73 |
| Quick Ratio | 1.74 | 2.17 | 5.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $33.76 Million | $ 21.08 Million | $ 14.65 Million |
Kuros Biosciences AG - Advanced Valuation Insights
This section examines the relationship between Kuros Biosciences AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.61 |
| Latest Market Cap to Assets Ratio | 7.03 |
| Asset Growth Rate (YoY) | 18.3% |
| Total Assets | $84.54 Million |
| Market Capitalization | $594.01 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Kuros Biosciences AG's assets at a significant premium ( 7.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Kuros Biosciences AG's assets grew by 18.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kuros Biosciences AG (2004–2024)
The table below shows the annual total assets of Kuros Biosciences AG from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $84.54 Million | +18.29% |
| 2023-12-31 | $71.46 Million | -13.84% |
| 2022-12-31 | $82.95 Million | -9.19% |
| 2021-12-31 | $91.34 Million | -3.21% |
| 2020-12-31 | $94.36 Million | +7.41% |
| 2019-12-31 | $87.85 Million | +2.37% |
| 2018-12-31 | $85.82 Million | -0.30% |
| 2017-12-31 | $86.08 Million | +96.68% |
| 2016-12-31 | $43.77 Million | +1242.99% |
| 2015-12-31 | $3.26 Million | -81.52% |
| 2014-12-31 | $17.63 Million | -56.47% |
| 2013-12-31 | $40.50 Million | +33.27% |
| 2012-12-31 | $30.39 Million | -1.37% |
| 2011-12-31 | $30.81 Million | -43.01% |
| 2010-12-31 | $54.07 Million | -21.30% |
| 2009-12-31 | $68.70 Million | -37.97% |
| 2008-12-31 | $110.75 Million | -10.36% |
| 2007-12-31 | $123.56 Million | +115.21% |
| 2006-12-31 | $57.41 Million | -30.32% |
| 2005-12-31 | $82.39 Million | -6.76% |
| 2004-12-31 | $88.37 Million | -- |